Clinical Trial Update: Study to Evaluate Arikace™ in CF Patients With Chronic Infection Due to Pseudomonas Aeruginosa [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating Arikace for chronic Pseudomonas aeruginosa infection in Cystic Fibrosis patients has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• Arikace

Snippet

Sponsor: Insmed Incorporated | Conditions: Cystic Fibrosis | Phase 3 | Status: WITHDRAWN